The rise of convertible notes in venture funding, largely due to Y Combinator's influence, has changed how early-stage companies raise capital.

Y Combinator is playing a significant role in funding young entrepreneurs in the biotech space, allowing them to advance their discoveries.

I've seen a lot of patterns in the startup ecosystem after funding 467 startups over the years.

I co-founded Y Combinator, the first startup accelerator, which began with a hypothesis about what people wanted, and it turned out they did want it, leading us to fund over 1,800 startups valued at over a hundred billion dollars.

The foundation of Y Combinator was based on the idea that it was becoming easier to build startups without needing massive capital or large teams, a trend that has accelerated with AI.

The shift from being seen as an underdog to a respected entity occurred around 2011, as companies began receiving larger investments, which changed perceptions of Y Combinator.

Many biotech companies have raised significantly more capital through Y Combinator than they would have in traditional biotech venture settings, with over $200 million raised for these companies.

Getting into Y Combinator was a turning point for us, as it validated our idea and pushed us to fully commit to the startup.

We were accepted into Y Combinator, which was a significant milestone for us and changed the course of our company.